Literature DB >> 932202

Fibrinopeptide A in plasma of normal subjects and patients with disseminated intravascular coagulation and systemic lupus erythematosus.

M Cronlund, J Hardin, J Burton, L Lee, E Haber, K J Bloch.   

Abstract

A radioimmunoassay for fibrinopeptide A (FPA) has been developed. This assay uses rabbit antibodies induced by injection of native FPA-human serum albumin conjugates and 125I introduced into tyrosine-FPA synthesized in out laboratory. Plasma FPA is separated from fibrinogen by TCA extraction. The assay is capable of detecting as little as 50 pg/ml of FPA. In 20 normal donors this assay revealed a mean concentration of 0.9 ng/ml (0.3 SD). In five patients with disseminated intravascular coagulation, FPA concentrations ranged from 13.0 to 346 ng/ml. Two groups of patients with systemic lupus erythematosus (SLE) whose disease had achieved complete remission were studied; one consisted of four patients with no history of lupus nephritis and another with a history of nephritis. Mean FPA concentrations of 1.5 ng/ml (range, 0.7-1.8 ng/ml) and 2.7 ng/ml (range, 1.1-5.6 ng/ml) were found in these two groups, respectively. Another group of nine patients with active SLE, but without evidence of lupus nephritis, had a mean FPA concentration of 4.5 ng/ml (range, 2.4-7.8 ng/ml). Finally, a group of seven patients with active SLE, including active nephritis, had a mean FPA concentration of 10.2 ng/ml (range, 5.3-17.0 ng/ml). A positive correlation was found between the concentration of plasma FPA and serum DNA-binding activity and an inverse correlation was found between plasma FPA and the concentration of serum C3. No correlation existed between plasma FPA and concentration of serum creatinine. Several possibilities for the origin of plasma FPA in patients with SLE were considered; at present it seems most likely that FPA arises through the action of thrombin on fibrinogen.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 932202      PMCID: PMC333165          DOI: 10.1172/JCI108443

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  The polymerization of proteins; the action of thrombin on fibrinogen.

Authors:  K LAKI
Journal:  Arch Biochem Biophys       Date:  1951-07       Impact factor: 4.013

2.  Competitive inhibitors of renin.

Authors:  K Poulsen; J Burton; E Haber
Journal:  Biochemistry       Date:  1973-09-25       Impact factor: 3.162

3.  Demonstration of fibrin in skin diseases. I. Lichen ruber planus and lupus erythematosus.

Authors:  O P Salo; T Tallberg; K K Mustakallio
Journal:  Acta Derm Venereol       Date:  1972       Impact factor: 4.437

Review 4.  Solid-phase peptide synthesis.

Authors:  R B Merrifield
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1969

5.  Fibrinogen catabolism studies in patients with renal disease.

Authors:  E N Wardle
Journal:  Q J Med       Date:  1973-01

6.  Split products of fibrin in human renal disease.

Authors:  E R Stiehm; C W Trygstad
Journal:  Am J Med       Date:  1969-05       Impact factor: 4.965

7.  Fibrinopeptide A immunoreactivity in human plasma.

Authors:  W B Gerrits; O T Flier; J van der Meer
Journal:  Thromb Res       Date:  1974-08       Impact factor: 3.944

8.  Platelet function and coagulation profile in lupus erythematosus. Studies in 50 patients.

Authors:  M G Regan; H Lackner; S Karpatkin
Journal:  Ann Intern Med       Date:  1974-10       Impact factor: 25.391

9.  Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation.

Authors:  L G Hunsicker; S Ruddy; C B Carpenter; P H Schur; J P Merrill; H J Müller-Eberhard; K F Austen
Journal:  N Engl J Med       Date:  1972-10-26       Impact factor: 91.245

10.  Measurement of fibrinopeptide A in human blood.

Authors:  H L Nossel; I Yudelman; R E Canfield; V P Butler; K Spanondis; G D Wilner; G D Qureshi
Journal:  J Clin Invest       Date:  1974-07       Impact factor: 14.808

View more
  10 in total

1.  Laboratory Measurement of Thrombin Activity--What Every Clinician Scientist Needs to Know.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

Review 2.  Candidate-based proteomics in the search for biomarkers of cardiovascular disease.

Authors:  Leigh Anderson
Journal:  J Physiol       Date:  2004-12-20       Impact factor: 5.182

3.  Leukocyte procoagulant activity: enhancement of production in vitro by IgG and antigen-antibody complexes.

Authors:  H Rothberger; T S Zimmerman; H L Spiegelberg; J H Vaughan
Journal:  J Clin Invest       Date:  1977-03       Impact factor: 14.808

4.  Specificity of fibrinopeptide A (FpA) as a marker for gastrointestinal cancers before and after surgery.

Authors:  V Abbasciano; F Levato; G Zavagli
Journal:  Med Oncol Tumor Pharmacother       Date:  1987

Review 5.  Relationships among the complement, kinin, coagulation, and fibrinolytic systems.

Authors:  J S Sundsmo; D S Fair
Journal:  Springer Semin Immunopathol       Date:  1983

6.  Haemostatic factors associated with vascular thrombosis in patients with systemic lupus erythematosus and the lupus anticoagulant.

Authors:  T Mayumi; K Nagasawa; T Inoguchi; Y Yamauchi; Y Ishii; Y Tada; F Umeda; Y Niho
Journal:  Ann Rheum Dis       Date:  1991-08       Impact factor: 19.103

7.  Plasminogen activation in plasma of patients with systemic lupus erythematosus.

Authors:  N Negoro; Y Kanayama; T Takeda; M Fujisawa; M Okamura; T Inoue
Journal:  Rheumatol Int       Date:  1989       Impact factor: 2.631

8.  Increased production and expression of tissue thromboplastin-like procoagulant activity in vitro by allogeneically stimulated human leukocytes.

Authors:  H Rothberger; T S Zimmerman; J H Vaughan
Journal:  J Clin Invest       Date:  1978-09       Impact factor: 14.808

9.  The generation of fibrinopeptide A in clinical blood samples: evidence for thrombin activity.

Authors:  H L Nossel; M Ti; K L Kaplan; K Spanondis; T Soland; V P Butler
Journal:  J Clin Invest       Date:  1976-11       Impact factor: 14.808

10.  Induction of monocyte procoagulant activity by murine hepatitis virus type 3 parallels disease susceptibility in mice.

Authors:  G A Levy; J L Leibowitz; T S Edgington
Journal:  J Exp Med       Date:  1981-10-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.